Ensysce Biosciences (ENSC) Net Income (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Net Income of -$3.7 million for Q3 2025, down 684.92% year-over-year from $640683.0 in Q3 2024, and down 113.69% quarter-over-quarter from -$1.8 million in Q2 2025.
Ensysce Biosciences (ENSC) Net Income (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Net Income for 8 consecutive years, with -$3.7 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Income fell 684.92% year-over-year to -$3.7 million; the TTM figure through Dec 2025 stood at -$7.5 million (up 6.74% YoY), while the FY2024 annual figure was -$8.0 million, up 35.48% from the prior year.
- Net Income retreated to -$3.7 million in Q3 2025 per ENSC's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Net Income topped out at $640683.0 in Q3 2024 and bottomed at -$54.1 million in Q2 2021.
- Historically, Net Income has averaged -$6.6 million across 5 years, with a median of -$3.1 million in 2024.
- On a YoY basis, Net Income climbed as much as 261.86% in 2021 and fell as far as 9162.76% in 2021.
- Ensysce Biosciences' Net Income stood at -$2.1 million in 2021, then slumped by 199.56% to -$6.3 million in 2022, then jumped by 49.85% to -$3.2 million in 2023, then fell by 13.22% to -$3.6 million in 2024, then slipped by 4.7% to -$3.7 million in 2025.
- Business Quant data shows ENSC's Net Income at -$3.7 million in Q3 2025, -$1.8 million in Q2 2025, and -$2.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.75 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -3.58 Mn |
| Sep 30, 2024 | 640,683.00 |
| Jun 30, 2024 | -1.98 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -2.71 Mn |
| Jun 30, 2023 | -2.29 Mn |
| Mar 31, 2023 | -2.56 Mn |
| Dec 31, 2022 | -6.30 Mn |
| Sep 30, 2022 | -6.17 Mn |
| Jun 30, 2022 | -7.10 Mn |
| Mar 31, 2022 | -4.82 Mn |
| Dec 31, 2021 | -2.10 Mn |
| Sep 30, 2021 | -19.83 Mn |
| Jun 30, 2021 | -54.13 Mn |
| Mar 31, 2021 | 566,288.00 |
| Dec 31, 2020 | 7.29 Mn |